Comparison of quadruple therapy and high dose dual therapy on Helicobacter pylori eradicatio
Phase 3
- Conditions
- Helicobacter pylori infection.Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhereB96.81
- Registration Number
- IRCT20131124015510N4
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
Inclusion criteria was ages between 18 and 80 years who have H. pylori positive and have endoscopic findings of gastric ulcer or erosion, duodenal ulcer or duodenitis and or histologic evidence of intestinal metaplasia.
Exclusion Criteria
Pregnant or nursing women, those with a history of upper GI surgery, major cardiac, lung, liver or renal diseases, a history of previous H. pylori eradication regimen and history of known side effects to the protocol drugs would be excluded.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Helicobacter pylori infection. Timepoint: In the beginning of the study when patient enrolled the study. Method of measurement: Evaluation of Helicobacter pylori infection by RUT test or pathology.
- Secondary Outcome Measures
Name Time Method Helicobacter pylori eradication. Timepoint: Six to 8 weeks after end of HP eradication treatment. Method of measurement: H pylori stool antigen test.